Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page

Q2 2024 Wellness & Aesthetic Medicine

Skip to the end of the Expertise Menu

Q2 2024 Wellness & Aesthetic Medicine

With the announcement of fifteen closed transactions, deal activity remains robust within the wellness and aesthetic medicine sector throughout Q2 2024. M&A was largely driven by strategic add-ons as platforms established in recent years continue to focus on geographic expansion.

Injectable treatments continue to be a meaningful value driver and complementary service to surgical and broader aesthetic providers. In one instance, Olympus Cosmetic Group, backed by VSS Capital Partners, partnered with Artisan Plastic Surgery and Artisan Beaute medspa. The ability to cross-sell services and increase the long-term value of customer relationships will likely contribute to the convergence of surgical and non-invasive services. Provident anticipates the vertical to remain active for the second half of 2024 as existing platforms prioritize growth via M&A and investors continue to seek new platforms.

To print and download the full Wellness & Aesthetic Medicine report, please click below…

[holo_button icon=”/wp-content/uploads/2024/07/Q2-2024-Aesthetics-vF.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]